Irene Eiseman

708 total citations
19 papers, 567 citations indexed

About

Irene Eiseman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Irene Eiseman has authored 19 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Irene Eiseman's work include HER2/EGFR in Cancer Research (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Irene Eiseman is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). Irene Eiseman collaborates with scholars based in United States, Canada and United Kingdom. Irene Eiseman's co-authors include Peter F. Lenehan, Lee F. Allen, Stephen C. Olson, Kenneth J. Tack, D. Fry, W ELLIOTT, Ghodrat A. Siami, N. V. Christou, Alberto Chiappori and Ralph Zinner and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Infectious Diseases and Clinical Cancer Research.

In The Last Decade

Irene Eiseman

19 papers receiving 537 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Irene Eiseman United States	11	370	234	178	120	45	19	567
Stephanie J. Gros Germany	16	362 1.0×	145 0.6×	272 1.5×	84 0.7×	23 0.5×	41	698
Joanna Regis United States	10	550 1.5×	47 0.2×	270 1.5×	52 0.4×	32 0.7×	14	660
E. Soresi Italy	13	255 0.7×	281 1.2×	212 1.2×	32 0.3×	14 0.3×	26	711
Seiji Doi Japan	12	511 1.4×	177 0.8×	365 2.1×	23 0.2×	13 0.3×	20	737
Lynne P. Rutzky United States	12	212 0.6×	41 0.2×	261 1.5×	164 1.4×	73 1.6×	18	893
Takeshi Kitazaki Japan	15	582 1.6×	254 1.1×	375 2.1×	23 0.2×	15 0.3×	37	896
Xiaofei Li China	17	344 0.9×	428 1.8×	144 0.8×	72 0.6×	24 0.5×	43	797
Sikic Bi United States	10	282 0.8×	58 0.2×	276 1.6×	22 0.2×	30 0.7×	13	547
Aruna Dontabhaktuni United States	10	216 0.6×	144 0.6×	152 0.9×	53 0.4×	7 0.2×	16	466
Hanfang Jiang China	12	301 0.8×	125 0.5×	182 1.0×	42 0.3×	12 0.3×	65	659

Countries citing papers authored by Irene Eiseman

Since Specialization

Citations

This map shows the geographic impact of Irene Eiseman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Irene Eiseman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Irene Eiseman more than expected).

Fields of papers citing papers by Irene Eiseman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Irene Eiseman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Irene Eiseman. The network helps show where Irene Eiseman may publish in the future.

Co-authorship network of co-authors of Irene Eiseman

This figure shows the co-authorship network connecting the top 25 collaborators of Irene Eiseman. A scholar is included among the top collaborators of Irene Eiseman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Irene Eiseman. Irene Eiseman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Jänne, Pasi A., Joachim von Pawel, Roger B. Cohen, et al.. (2007). Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(25). 3936–3944. 93 indexed citations

2.

Zinner, Ralph, John Nemunaitis, Irene Eiseman, et al.. (2007). Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clinical Cancer Research. 13(10). 3006–3014. 20 indexed citations

3.

Chiappori, Alberto, Peter Ellis, John Hamm, et al.. (2006). A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1010–1019. 12 indexed citations

4.

Simon, George R., Christopher R. Garrett, Stephen C. Olson, et al.. (2006). Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study. Clinical Cancer Research. 12(15). 4645–4651. 22 indexed citations

5.

Chiappori, Alberto, Peter Ellis, John Hamm, et al.. (2006). A Phase I Evaluation of Oral CI-1033 in Combination with Paclitaxel and Carboplatin as First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 1(9). 1010–1019. 9 indexed citations

6.

Garland, Linda L., Manuel Hidalgo, David S. Mendelson, et al.. (2006). A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12(14). 4274–4282. 26 indexed citations

7.

Eder, Joseph P., Manuel Hidalgo, David S. Mendelson, et al.. (2005). A phase I clinical and pharmacokinetic (PK) study of oral CI-1033 + docetaxel (DOC) in the treatment of patients with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3111–3111. 2 indexed citations

8.

Nemunaitis, John, Irene Eiseman, Casey Cunningham, et al.. (2005). Phase 1 Clinical and Pharmacokinetics Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clinical Cancer Research. 11(10). 3846–3853. 71 indexed citations

9.

Levine, Donald P., H. Preston Holley, Irene Eiseman, Paul A. Willcox, & Kenneth J. Tack. (2004). Clinafloxacin for the Treatment of Bacterial Endocarditis. Clinical Infectious Diseases. 38(5). 620–631. 8 indexed citations

10.

Calvo, Emiliano, Anthony W. Tolcher, Lisa A. Hammond, et al.. (2004). Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule. Clinical Cancer Research. 10(21). 7112–7120. 68 indexed citations

11.

Simon, George R., S.C. Olson, Chris R. Garrett, et al.. (2004). Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3057–3057. 5 indexed citations

12.

Simon, George R., Sarah Olson, Chris R. Garrett, et al.. (2004). Phase I pharmacokinetic (PK) and safety study of intravenous (IV) CI-1033 in patients with advanced solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3057–3057. 4 indexed citations

13.

Allen, Lee F., et al.. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Seminars in Oncology. 29(3). 11–21. 83 indexed citations

14.

Allen, Lee F., Peter F. Lenehan, Irene Eiseman, William L. Elliott, & David W. Fry. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Seminars in Oncology. 29(3 Suppl 11). 11–21. 52 indexed citations

15.

Siami, Ghodrat A., et al.. (2001). Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections. Antimicrobial Agents and Chemotherapy. 45(2). 525–531. 62 indexed citations

16.

Randinitis, Edward J., Joanne Brodfuehrer, Irene Eiseman, & Artemios B. Vassos. (2001). Pharmacokinetics of Clinafloxacin after Single and Multiple Doses. Antimicrobial Agents and Chemotherapy. 45(9). 2529–2535. 9 indexed citations

17.

Tack, Kenneth J., Nancy M. McGuire, & Irene Eiseman. (1995). Initial Clinical Experience with Clinafloxacin in the Treatment of Serious Infections. Drugs. 49(Supplement 2). 488–491. 16 indexed citations

18.

Eiseman, Irene, et al.. (1986). A validated liquid chromatographic method for the antiallergy agent CI-922 in dog and rat plasma. Journal of Pharmaceutical and Biomedical Analysis. 4(4). 491–496. 1 indexed citations

19.

Glazko, Anthony J., et al.. (1983). Bioavailability of Calcium Valproate in Normal Men Compared with the Free Acid and Sodium Salt. Therapeutic Drug Monitoring. 5(4). 409–418. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact